Business Context and Reporting Period
This Form 8-K Current Report was filed by Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) on January 28, 2025. The filing reports a corporate governance event involving the appointment of a new director and committee members.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes
The primary material change reported is the appointment of Daniel Baker, Ph.D., as a Class I director and a member of the Clinical Strategy Committee. Concurrently, Laura Bessen, M.D., Brian Daniels, M.D., and Laural Stoppel, Ph.D., were appointed as members of the Clinical Strategy Committee, with Diego Miralles, M.D., appointed as chair.
Management Commentary and Compensation Details
Dr. Baker brings significant industry experience, including 19 years at Johnson & Johnson and recent roles at Cue Biopharma and Kira Biotech. His compensation package includes:
- Annual Cash Retainer: $40,000 for Board service.
- Initial Option Grant: 27,500 shares of common stock. One-third vested immediately; the remainder vests monthly over two years.
- Future Grants: Automatic annual grants of 13,750 shares on the date of each annual meeting, vesting in full after one year or at the next meeting.
- Committee Retainers: $7,500 annually for Clinical Strategy Committee members; $15,000 annually for the Committee Chair.
- Change in Control: All option grants vest in full upon a change in control.
Dr. Baker has also entered into the Company's standard Indemnification Agreement. No other transactions requiring disclosure under Item 404(a) were identified.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 27,500 share option grant to Dr. Baker in the Company's 2024 Equity Incentive Plan.
- Confirm the total number of authorized shares available for issuance under the Equity Incentive Plan to assess dilution impact.
- Review the Company's most recent 10-K or 10-Q for current cash runway and liquidity status, as this 8-K does not contain financial data.
- Monitor the composition of the Clinical Strategy Committee for future strategic shifts in clinical development.